RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Guangdong Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07327216, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07327216, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

  • Inclusion Criteria:
  • Stage III-IVa NPC (AJCC 8th edition) diagnosed via pathology in a tertiary hospital;
  • No previous radiotherapy, chemotherapy, surgery, immunization, or targeted therapy;
  • Karnofsky Performance Status score ≥80;
  • Intact and normal oral mucosa before treatment;
  • Age 18-75 years;
  • Voluntary participation and provision of informed consent in person;
  • Routine blood examination: white blood cell count ≥4.0×109/L, hemoglobin ≥100g/L, neutrophil count ≥1.5×10\^9/L, and platelet count ≥100×10\^9/L;
  • Biochemical examination: total bilirubin ≤1.5×the upper limit of the normal range (ULN), alanine aminotransferase and aspartate aminotransferase ≤2×ULN, and estimated glomerular filtration rate ≥60 mL/min.
  • Exclusion Criteria:
  • With other malignant tumors in the past or present and/or distant metastasis during treatment;
  • Who have undergone surgery, chemoradiotherapy, and targeted immunotherapy;
  • With a history of asthma, rash, urticaria, and other allergic diseases;
  • With a history of autoimmune diseases, connective tissue diseases, and diabetes mellitus that significantly affect the healing of the oral mucosa;
  • With concomitant diseases, such as heart disease, kidney disease, and acute infectious diseases, which are judged by the investigator to seriously endanger the safety of patients or affect the completion of the study;
  • Who are breastfeeding, pregnant, or planning to become pregnant during the study;
  • With known allergies to the therapeutic agents and penicillin used in the trial;
  • Mental or nervous system diseases or poor compliance.

Quoted from ClinicalTrials.gov, NCT07327216, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07327216, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07327216